- Home
- GAIN vs TSHA Comparison
GAIN vs TSHA Comparison
Compare GAIN & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAIN
- TSHA
- Stock Information
- Founded
- GAIN 2005
- TSHA 2019
- Country
- GAIN United States
- TSHA United States
- Employees
- GAIN N/A
- TSHA N/A
- Industry
- GAIN Finance: Consumer Services
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- GAIN Finance
- TSHA Health Care
- Exchange
- GAIN Nasdaq
- TSHA Nasdaq
- Market Cap
- GAIN 473.7M
- TSHA 403.7M
- IPO Year
- GAIN 2005
- TSHA 2020
- Fundamental
- Price
- GAIN $13.14
- TSHA $2.03
- Analyst Decision
- GAIN Hold
- TSHA Strong Buy
- Analyst Count
- GAIN 2
- TSHA 8
- Target Price
- GAIN $13.75
- TSHA $6.63
- AVG Volume (30 Days)
- GAIN 118.8K
- TSHA 5.4M
- Earning Date
- GAIN 02-04-2025
- TSHA 11-13-2024
- Dividend Yield
- GAIN 7.30%
- TSHA N/A
- EPS Growth
- GAIN N/A
- TSHA N/A
- EPS
- GAIN 1.06
- TSHA N/A
- Revenue
- GAIN $91,472,000.00
- TSHA $9,915,000.00
- Revenue This Year
- GAIN $5.77
- TSHA N/A
- Revenue Next Year
- GAIN $3.37
- TSHA N/A
- P/E Ratio
- GAIN $12.40
- TSHA N/A
- Revenue Growth
- GAIN 11.51
- TSHA N/A
- 52 Week Low
- GAIN $12.46
- TSHA $1.19
- 52 Week High
- GAIN $14.96
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- GAIN 35.22
- TSHA 42.15
- Support Level
- GAIN $13.46
- TSHA $1.97
- Resistance Level
- GAIN $13.92
- TSHA $2.72
- Average True Range (ATR)
- GAIN 0.22
- TSHA 0.24
- MACD
- GAIN -0.04
- TSHA -0.10
- Stochastic Oscillator
- GAIN 8.24
- TSHA 4.48
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to (i) achieve and grow current income by investing in debt securities of established businesses. (ii) provide our stockholders with long-term capital appreciation in the value of our assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.